Home > Boards > Free Zone > User's Groups > Gold Medal Penny Stocks

$ARFXF news on COVID antibody test launch

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Gbathat Member Profile
Followed By 10
Posts 1,330
Boards Moderated 0
Alias Born 06/05/07
160x600 placeholder
Dow Inc. Up Over 6%, Best Performer in the DJIA So Far Today -- Data Talk
Dow, Inc. (DOW) is currently at $60.23, up $3.42 or 6.02% -- Would be highest close since Sept. 13, 2021, when it closed at $60.72
Safran Appoints New CFO
Top Company News of the Day
STOXX Europe 600 Index Ends 0.19% Lower at 462.42 -- Data Talk
FTSE 100 Index Ends 0.17% Higher at 7063.40 -- Data Talk
DAX Ends 0.27% Higher at 15573.88 -- Data Talk
CAC 40 Index Ends 0.19% Higher at 6650.91 -- Data Talk
STOXX Europe 50 Index Ends 0.08% Lower at 3547.57 -- Data Talk
EURO STOXX 50 Index Ends 0.17% Higher at 4165.48 -- Data Talk
FTSE 100 Gets Boost From Energy Stocks
TotalEnergies Expects Global Oil Demand to Plateau Before 2030
Petrofac Sentencing Hearing for Bribery Delayed to End of Week
NASA Pact Launches Red Cat Shares Up Nearly 70%
French Court to Rule on UBS Tax-Evasion Case in December
Texas Factory Output Picked Up Steam in September -- Dallas Fed
YouTube TV Could Lose NBCUniversal Programming If Deal Isn't Reached by Thursday
UK Watchdog Won't Refer Facebook's Planned Kustomer Buy for Further Review
FTSE 100 Flat, Oil Majors Rise as Supply Jitters Boost Crude Prices
Durable Goods Orders Rise Sharply in August Despite Continued Supply Constraints
Ultragenyx, GeneTx: FDA Removes Hold Study of GTX-102 in Angelman Syndrome
Blackstone to Sell The Cosmopolitan of Las Vegas for $5.65 Billion
Lockheed Martin, Pentagon Agree to F-35 Production Rebaseline
Shell Energy Takes 255,000 Customers of Collapsed UK Retailer
Bristol Myers Squibb: FDA to Review Opdivo Combos in Esophageal Squamous Cell Carcinoma
Merck Says Keytruda Liver Cancer Study Meets Objective
BASF's Zhanjiang Site Seen Generating Up to $5 Billion in Annual Sales
Gbathat   Tuesday, 05/25/21 08:51:44 PM
Re: None
Post # of 16124 
$ARFXF news on COVID antibody test launch

ProMIS initiates commercialization of COVID-19 assay
ProMIS Neurosciences initiates commercialization of COVID-19 serology assay

TORONTO and CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN); (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, today announced that it has initiated commercialization of its COVID-19 serology assay and has appointed Owen Dempsey to lead the commercialization program.

Owen’s professional work for the past 25 years has been to build companies founded to discover and commercialize antibodies in applications including life science research, pharmaceutical drug discovery, clinical diagnostics and therapeutic treatment of cancer, AIDS and other serious illness. He has led private, venture-backed as well as NASDAQ-listed companies and is a past board member of ALDA, the Analytical, Life Science & Diagnostics Association.

“I am delighted to lead this opportunity on behalf of ProMIS Neurosciences,” stated Owen Dempsey. “Our serology assay commercialization efforts will be targeting the need for a highly accurate test to detect, quantify and characterize antibodies against the virus causing COVID-19, either as a consequence of contracting the viral disease or in response to vaccination. Our initial focus will be on commercialization to the medical and public health community, vaccine developers, pharmaceutical companies, governmental agencies and other organizations.”

This advanced serology test developed by ProMIS Neurosciences measures not only serum antibodies to SARS-CoV-2, the novel coronavirus causing COVID-19, but also their protective activity against infection. The assay simultaneously assesses antibody levels in the blood of study participants and their neutralizing activity against the original strain of SARS-CoV-2 as well as emerging variants. Additional variants can be added to the assay as they are identified. The assay utilizes an advanced, high-throughput, sensitive and accurate surface plasmon resonance (SPR) technology as opposed to traditional ELISA (enzyme-linked immunosorbent assay) methods.

In commercializing an advanced serology testing platform, we aim to meet the needs of the medical community and investigators in academia, industry and government working to assess response and durability of response to vaccines as well as to monitor and assess antibody response to emerging strains of the virus.. As reported in the scientific literature, our accurate and sensitive format is capable of measuring neutralizing antibodies that inhibit coronavirus RBD binding to the human ACE2 receptor. This provides a powerful surrogate measure of antibody immunity without the need for live virus or pseudovirus formats. This and similar collaborative efforts may help to guide the need for boosters or modified vaccines addressing emerging strains and will inform the medical community’s preparedness to meet similar public threats to global health in the years ahead.

It is important to note, as stated above that the initial marketing and commercialization of the assay will be directed only to organizations such as vaccine manufacturers, pharmaceutical companies and government organizations at the national and state/provincial level. The assay is not currently available to private individual consumers or the general public.

God grant me the serenity to deal with the things I cannot change; courage to change the things I can and should; and wisdom to know the difference.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences